KR101842907B1 - 제 ⅰ형 인터페론을 생산하는 세포를 표적화하기 위한 조성물 및 방법 - Google Patents

제 ⅰ형 인터페론을 생산하는 세포를 표적화하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR101842907B1
KR101842907B1 KR1020127024197A KR20127024197A KR101842907B1 KR 101842907 B1 KR101842907 B1 KR 101842907B1 KR 1020127024197 A KR1020127024197 A KR 1020127024197A KR 20127024197 A KR20127024197 A KR 20127024197A KR 101842907 B1 KR101842907 B1 KR 101842907B1
Authority
KR
South Korea
Prior art keywords
immunoglobulin
ser
days
antibody
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127024197A
Other languages
English (en)
Korean (ko)
Other versions
KR20130004576A (ko
Inventor
지노 루이지 바이로
앤드류 내쉬
유진 마라스코브스키
닉 윌슨
사만타 버스필드
콘 파노우시즈
Original Assignee
씨에스엘 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44482392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101842907(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US12/707,297 external-priority patent/US20100209341A1/en
Application filed by 씨에스엘 리미티드 filed Critical 씨에스엘 리미티드
Publication of KR20130004576A publication Critical patent/KR20130004576A/ko
Application granted granted Critical
Publication of KR101842907B1 publication Critical patent/KR101842907B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020127024197A 2010-02-17 2011-02-17 제 ⅰ형 인터페론을 생산하는 세포를 표적화하기 위한 조성물 및 방법 Active KR101842907B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US12/707,297 US20100209341A1 (en) 2009-02-18 2010-02-17 Treatment of chronic inflammatory conditions
US12/707,297 2010-02-17
US37449710P 2010-08-17 2010-08-17
US37448910P 2010-08-17 2010-08-17
US61/374,489 2010-08-17
US61/374,497 2010-08-17
PCT/AU2011/000155 WO2011100786A1 (en) 2010-02-17 2011-02-17 Compositions and methods for targeting type 1 interferon producing cells

Publications (2)

Publication Number Publication Date
KR20130004576A KR20130004576A (ko) 2013-01-11
KR101842907B1 true KR101842907B1 (ko) 2018-03-28

Family

ID=44482392

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127024197A Active KR101842907B1 (ko) 2010-02-17 2011-02-17 제 ⅰ형 인터페론을 생산하는 세포를 표적화하기 위한 조성물 및 방법

Country Status (10)

Country Link
EP (1) EP2536430B1 (enExample)
JP (1) JP6018507B2 (enExample)
KR (1) KR101842907B1 (enExample)
CN (1) CN103002913B (enExample)
AU (1) AU2011217728B2 (enExample)
CA (1) CA2789810C (enExample)
ES (1) ES2618562T3 (enExample)
IL (1) IL221504B (enExample)
NZ (2) NZ601760A (enExample)
WO (1) WO2011100786A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100209341A1 (en) 2009-02-18 2010-08-19 Csl Limited Treatment of chronic inflammatory conditions
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
TN2018000324A1 (en) 2015-01-23 2020-01-16 Sanofi Sa ANTl-CD3 ANTIBODIES, ANTl-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123
TW201709932A (zh) 2015-06-12 2017-03-16 西雅圖遺傳學公司 Ｃｄ１２３抗體及其共軛物
EP3448995A1 (en) * 2016-04-25 2019-03-06 Universität Basel Allele editing and applications thereof
EP3856764A4 (en) 2018-09-27 2022-11-02 Xilio Development, Inc. MASKED CYTOKINE POLYPEPTIDES
CA3196844A1 (en) 2020-11-25 2022-06-02 Raphael Rozenfeld Tumor-specific cleavable linkers
AU2021414400A1 (en) 2020-12-31 2023-08-17 Innate Pharma Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123
AU2023274452A1 (en) 2022-05-27 2025-01-16 Innate Pharma Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008127735A1 (en) * 2007-04-13 2008-10-23 Stemline Therapeutics, Inc. Il3ralpha antibody conjugates and uses thereof
WO2009070844A1 (en) * 2007-12-06 2009-06-11 Csl Limited Method of inhibition of leukemic stem cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002305452A1 (en) * 2001-05-08 2002-11-18 Emory University Regulating immine responses using dendritic cells
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP3520806B1 (en) * 2006-09-07 2024-03-20 Scott & White Memorial Hospital Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
JP2008162954A (ja) * 2006-12-28 2008-07-17 Kirin Pharma Co Ltd 形質細胞様樹状細胞特異的膜分子に対する抗体を含む治療剤
US20100209341A1 (en) * 2009-02-18 2010-08-19 Csl Limited Treatment of chronic inflammatory conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008127735A1 (en) * 2007-04-13 2008-10-23 Stemline Therapeutics, Inc. Il3ralpha antibody conjugates and uses thereof
WO2009070844A1 (en) * 2007-12-06 2009-06-11 Csl Limited Method of inhibition of leukemic stem cells

Also Published As

Publication number Publication date
IL221504B (en) 2019-06-30
WO2011100786A1 (en) 2011-08-25
CA2789810C (en) 2020-12-01
NZ610826A (en) 2015-01-30
AU2011217728A1 (en) 2012-09-06
EP2536430B1 (en) 2016-12-14
ES2618562T3 (es) 2017-06-21
CA2789810A1 (en) 2011-08-25
NZ601760A (en) 2013-10-25
KR20130004576A (ko) 2013-01-11
EP2536430A1 (en) 2012-12-26
JP2013519690A (ja) 2013-05-30
CN103002913B (zh) 2015-12-16
JP6018507B2 (ja) 2016-11-02
EP2536430A4 (en) 2013-09-04
CN103002913A (zh) 2013-03-27
AU2011217728B2 (en) 2013-03-14

Similar Documents

Publication Publication Date Title
US9758585B2 (en) Compositions and methods for targeting type 1 interferon producing cells
JP6889741B2 (ja) 抗血液樹状細胞抗原２抗体およびその使用
US10047161B2 (en) Humanized anti-interleukin 3 receptor alpha chain antibodies
KR101842907B1 (ko) 제 ⅰ형 인터페론을 생산하는 세포를 표적화하기 위한 조성물 및 방법
US20160031996A1 (en) Anti il-3r alpha agents and uses thereof
AU2013200910B2 (en) Composition and methods for targeting type 1 interferon producing cells
HK1179884A (en) Compositions and methods for targeting type 1 interferon producing cells
HK1179884B (en) Compositions and methods for targeting type 1 interferon producing cells
HK40031865A (en) Anti-blood dendritic cell antigen 2 antibodies and uses thereof
HK1216027B (en) Anti-blood dendritic cell antigen 2 antibodies and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120917

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20151201

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170303

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170926

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170303

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20170926

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20170828

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20151201

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20180103

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20171226

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20170926

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20170828

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20151201

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20180322

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20180323

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20210218

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20220216

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20240110

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20250106

Start annual number: 8

End annual number: 8